OBJECTIVE: To examine temporal trends in mortality rates in a large nationwide cohort of patients with end-stage renal disease (ESRD) due to granulomatosis with polyangiitis (Wegener's) (GPA-ESRD). METHODS: We identified cases of GPA-ESRD reported in the US Renal Data System between 1995 and 2014, using coding by nephrologists for the cause of ESRD. The cohort was divided into four 5-year subcohorts based on the year of onset of ESRD (1995-1999, 2000-2004, 2005-2009, and 2010-2014) to assess trends in mortality rates and hazard ratios (HRs) for overall death and cause-specific death, adjusting for potential confounders. RESULTS: Between 1995 and 2014, there were 5,929 incident cases of GPA-ESRD. The mortality rate (incidence per 100 patient-years) declined from 19.0 in 1995-1999 to 15.3 in 2010-2014 (P for trend = 0.01). The multivariable-adjusted HR for mortality in the 2010-2014 cohort was 0.77 (95% confidence interval [95% CI] 0.66-0.90) (P for trend < 0.001 versus the 1995-1999 cohort). The corresponding cause-specific HRs for mortality, after accounting for competing risk, were 0.61 (95% CI 0.47-0.80) for CVD-related death and 0.42 (95% CI 0.28-0.63) for death due to infection (P for trend < 0.001). CONCLUSION: In this study of nearly all patients in whom GPA-ESRD developed in the US over 2 decades, we observed significant improvements in mortality among GPA-ESRD patients. The number of cause-specific deaths due to CVD and the number due to infections declined significantly during the study period. These findings are encouraging and likely reflect improved management of both GPA and ESRD.
OBJECTIVE: To examine temporal trends in mortality rates in a large nationwide cohort of patients with end-stage renal disease (ESRD) due to granulomatosis with polyangiitis (Wegener's) (GPA-ESRD). METHODS: We identified cases of GPA-ESRD reported in the US Renal Data System between 1995 and 2014, using coding by nephrologists for the cause of ESRD. The cohort was divided into four 5-year subcohorts based on the year of onset of ESRD (1995-1999, 2000-2004, 2005-2009, and 2010-2014) to assess trends in mortality rates and hazard ratios (HRs) for overall death and cause-specific death, adjusting for potential confounders. RESULTS: Between 1995 and 2014, there were 5,929 incident cases of GPA-ESRD. The mortality rate (incidence per 100 patient-years) declined from 19.0 in 1995-1999 to 15.3 in 2010-2014 (P for trend = 0.01). The multivariable-adjusted HR for mortality in the 2010-2014 cohort was 0.77 (95% confidence interval [95% CI] 0.66-0.90) (P for trend < 0.001 versus the 1995-1999 cohort). The corresponding cause-specific HRs for mortality, after accounting for competing risk, were 0.61 (95% CI 0.47-0.80) for CVD-related death and 0.42 (95% CI 0.28-0.63) for death due to infection (P for trend < 0.001). CONCLUSION: In this study of nearly all patients in whom GPA-ESRD developed in the US over 2 decades, we observed significant improvements in mortality among GPA-ESRDpatients. The number of cause-specific deaths due to CVD and the number due to infections declined significantly during the study period. These findings are encouraging and likely reflect improved management of both GPA and ESRD.
Authors: Zdenka Hruskova; Vianda S Stel; David Jayne; Knut Aasarød; Johan De Meester; Agneta Ekstrand; Kathrin Eller; James G Heaf; Andries Hoitsma; Carmen Martos Jimenéz; Pietro Ravani; Christoph Wanner; Vladimir Tesar; Kitty J Jager Journal: Am J Kidney Dis Date: 2015-05-12 Impact factor: 8.860
Authors: Sofia Lionaki; Susan L Hogan; Caroline E Jennette; Yichun Hu; Julie B Hamra; J Charles Jennette; Ronald J Falk; Patrick H Nachman Journal: Kidney Int Date: 2009-06-17 Impact factor: 10.612
Authors: Rennie L Rhee; Susan L Hogan; Caroline J Poulton; Julie Anne G McGregor; J Richard Landis; Ronald J Falk; Peter A Merkel Journal: Arthritis Rheumatol Date: 2016-07 Impact factor: 10.995
Authors: J Antonio Aviña-Zubieta; Alice Mai; Neda Amiri; Natasha Dehghan; Ju Ann Tan; Eric C Sayre; Hyon K Choi Journal: Arthritis Rheumatol Date: 2016-09-29 Impact factor: 10.995
Authors: M Yates; R A Watts; I M Bajema; M C Cid; B Crestani; T Hauser; B Hellmich; J U Holle; M Laudien; M A Little; R A Luqmani; A Mahr; P A Merkel; J Mills; J Mooney; M Segelmark; V Tesar; K Westman; A Vaglio; N Yalçındağ; D R Jayne; C Mukhtyar Journal: Ann Rheum Dis Date: 2016-06-23 Impact factor: 27.973
Authors: Zachary S Wallace; Rachel Wallwork; Yuqing Zhang; Na Lu; Frank Cortazar; John L Niles; Eliot Heher; John H Stone; Hyon K Choi Journal: Ann Rheum Dis Date: 2018-05-14 Impact factor: 19.103
Authors: Germán Sánchez-Díaz; Francisco Escobar; Ana Villaverde-Hueso; Manuel Posada de la Paz; Verónica Alonso-Ferreira Journal: Int J Environ Res Public Health Date: 2019-04-17 Impact factor: 3.390